Genetic Factors in Atherosclerosis

Genetic Architecture

• The European Heart Journal suggests that genetic polymorphisms, including single nucleotide polymorphisms (SNPs), insertion/deletion variants, and copy number variants, collectively influence disease risk, with approximately 20 genes explaining 50% of disease burden 1
• The Lipoprotein(a) [Lp(a)] gene represents a major genetic factor for coronary heart disease, with effects of similar magnitude to smoking 1
• Factor V gene variants and prothrombin gene variants show moderate association with coronary disease risk in large meta-analyses 1
• CRP genotypes coding for higher circulating CRP levels are not associated with cardiovascular disease, despite observational associations with CRP levels themselves 1

Clinical Translation of Family History

• A positive family history increases baseline cardiovascular disease risk by 1.5-2.0 fold independent of classical risk factors, according to the European Heart Journal 1
• The American Academy of Pediatrics, as cited in Pediatrics, defines premature disease in male first-degree relatives with events before age 55 years and female first-degree relatives with events before age 65 years 2, 3
• Events include: heart attack, treated angina, percutaneous coronary intervention, coronary artery bypass surgery, stroke, or sudden cardiac death, as defined by the American Academy of Pediatrics, as cited in Pediatrics 2, 3

Pediatric Screening

• The American Academy of Pediatrics, as cited in Pediatrics, recommends obtaining fasting lipid panel (FLP) at ages 1-4 years only if family history for CVD is positive, parent has dyslipidemia, or child has other risk factors 2
• The American Academy of Pediatrics, as cited in Pediatrics, recommends obtaining FLP at ages 5-9 years only if family history for CVD is positive 2
• The American Academy of Pediatrics, as cited in Pediatrics, recommends obtaining FLP at ages 9-11 years and 12-17 years if family history newly becomes positive 2

Current Limitations and Future Directions

• DNA-based tests do not currently add significantly to diagnostic utility or patient management beyond what family history and phenotypic assessment provide, according to the European Heart Journal 1
• Understanding genetic determinants may eventually identify high-risk individuals and enable personalized therapeutic management, as suggested by the European Heart Journal 1

Critical Pitfalls to Avoid

• Do not overlook maternal family history, as the association applies equally to male and female relatives and has been confirmed across different racial and ethnic groups, according to the American Academy of Pediatrics, as cited in Pediatrics 2, 3
• Do not delay aggressive risk factor modification in patients with strong family history while awaiting genetic test results that currently lack clinical utility, as advised by the European Heart Journal 1

Premature Atherosclerotic Disease Definition and Management

Introduction to Premature Atherosclerotic Disease

• The American College of Cardiology defines premature atherosclerotic disease as coronary artery disease occurring before age 55 years in men and before age 65 years in women, particularly when affecting first-degree relatives 4, 5
• The American College of Cardiology and American Heart Association have established clear age cutoffs that define premature disease: men with disease onset before age 55 years and women with disease onset before age 65 years constitute premature coronary heart disease 4, 5

Clinical Significance and Risk Implications

• The presence of premature atherosclerotic disease in a first-degree relative dramatically elevates an individual's cardiovascular risk, increasing by 1.5- to 2.0-fold independent of other traditional risk factors 4, 5
• Approximately 75% of patients with premature coronary heart disease have a positive family history, demonstrating the strong hereditary component 4, 5
• The Canadian Cardiovascular Society recommends doubling a person's estimated risk when they have a family history of premature atherosclerotic cardiovascular disease 5

Pediatric Context and High-Risk Conditions

• The American Heart Association has stratified certain childhood conditions into risk tiers based on evidence of manifest coronary artery disease occurring at age 30 years or younger 6
• Tier I (High Risk) conditions include: homozygous familial hypercholesterolemia, type 1 diabetes mellitus, chronic kidney disease/end-stage renal disease, post-heart transplantation, and Kawasaki disease with current coronary aneurysms 6
• Tier II (Moderate Risk) conditions include: heterozygous familial hypercholesterolemia, type 2 diabetes mellitus, Kawasaki disease with regressed coronary aneurysms, and chronic inflammatory disease 6

Screening and Management Implications

• The American College of Cardiology recommends screening all first-degree relatives of patients who developed coronary heart disease before age 55 (men) or 65 (women) 4
• The American Heart Association recommends beginning lipid screening at age 20 rather than age 40 in adults with a family history of premature cardiovascular disease 5
• The American Academy of Pediatrics recommends measuring blood pressure annually from age 3 in children with a family history of early cardiovascular disease 5
• Multifactorial cardiovascular risk will be higher than estimated from standard risk calculators in individuals with a family history of premature cardiovascular disease 4
• Coronary artery calcium scoring should be considered for patients with a family history of premature coronary artery disease and a low global coronary artery disease risk score 5

Cardiovascular Disease Screening with Strong Family History

Initial Screening Age Based on Family History

• The American Heart Association recommends starting comprehensive cardiovascular risk screening at age 20 if you have heart disease and heart attacks documented on both maternal and paternal sides of your family, which includes assessments such as fasting lipid profile, blood pressure measurement, fasting blood glucose, body mass index and waist circumference, smoking status assessment, and physical activity and diet evaluation 7
• Individuals with a strong bilateral family history of premature cardiovascular disease have a 1.5- to 2.0-fold increased baseline risk independent of other risk factors, justifying earlier and more aggressive screening than the general population 8

Definition of Premature Family History That Triggers Early Screening

• A family history qualifies as "premature" and high-risk if male first-degree relatives had heart attacks, coronary interventions, or sudden cardiac death before age 55, or female first-degree relatives had these events before age 65 8

Screening Frequency and Follow-Up

• The American College of Cardiology recommends repeating screening intervals every 2 years if any risk factors are present or lipid levels approach treatment thresholds, every 5 years minimum even if initial results are normal, and more frequently if you develop diabetes, hypertension, or other cardiovascular risk factors 7

Comprehensive Risk Assessment at Age 40

• At age 40, undergo formal 10-year cardiovascular risk calculation using a multivariable risk score that incorporates age, sex, smoking status, systolic and diastolic blood pressure, total cholesterol, LDL cholesterol, HDL cholesterol, and presence of diabetes 7

Three-Generation Family History Documentation

• The American College of Cardiology recommends obtaining and regularly updating a detailed 3-generation family history that includes all cardiovascular events in parents, siblings, grandparents, aunts, uncles, age at which events occurred, type of events, and presence of risk factors in relatives 9, 10